Table of Contents
Preparing for exams can be challenging, especially when it comes to memorizing complex pharmacological profiles. Dapagliflozin, a medication used in the management of type 2 diabetes, has a unique mechanism of action and pharmacokinetic properties that are essential for students to understand. This article simplifies its pharmacological profile to aid in effective memorization.
What is Dapagliflozin?
Dapagliflozin is an oral antihyperglycemic agent classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It helps lower blood glucose levels by promoting glucose excretion through the urine.
Mechanism of Action
The drug inhibits the SGLT2 proteins in the proximal tubules of the kidneys. This inhibition prevents glucose reabsorption, leading to increased urinary glucose excretion and decreased blood glucose levels.
Key Points of Mechanism
- Targets SGLT2 in renal tubules
- Reduces renal glucose reabsorption
- Increases urinary glucose excretion
- Lowers plasma glucose levels
Pharmacokinetics
Dapagliflozin has specific absorption, distribution, metabolism, and excretion characteristics that are important for understanding its use and effects.
Absorption
It is rapidly absorbed with peak plasma concentrations reached within 2 hours after oral administration.
Distribution
Dapagliflozin is highly protein-bound (>91%), mainly to albumin, which influences its distribution and elimination.
Metabolism
It undergoes minimal metabolism, with the majority excreted unchanged in the urine and feces.
Excretion
Approximately 80% of the drug is eliminated via the feces, and about 20% via the urine. The half-life is approximately 13 hours, supporting once-daily dosing.
Common Uses and Benefits
Dapagliflozin is primarily used to improve glycemic control in adults with type 2 diabetes. Its benefits include weight loss and a low risk of hypoglycemia when used alone or with other medications.
Side Effects and Precautions
Common side effects include urinary tract infections, genital mycotic infections, and increased urination. Rare but serious risks involve ketoacidosis and dehydration. Patients with renal impairment require dose adjustments or may not be suitable candidates.
Summary for Memorization
- Drug class: SGLT2 inhibitor
- Mechanism: Blocks renal glucose reabsorption
- Peak plasma: 2 hours
- Protein binding: >91%
- Metabolism: Minimal
- Excretion: Mainly feces, some urine
- Dosing: Once daily